RDGLOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

Vivos Inc

Vivos Inc. is a U.S.-based radiation oncology medical device company focused on yttrium-90 (Y-90) precision radionuclide therapy technologies for treating non-resectable tumors. Its core platform includes RadioGel™ and related brachytherapy and isotope-based products developed for use in human and animal cancer treatment.

Kysy yhtiöstä
Liikevaihto0,1milj. USD
+144,3 %v/v
Liikevoitto (EBIT)−3,2milj. USD
−21,5 %v/v
EBIT-marginaali−4 628,7%
+4 674,3 %-yks.v/v
Nettotulos−3,1milj. USD
−5,3 %v/v
Vapaa kassavirta−2,2milj. USD
−28,3 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−4−3−2−101milj. USD2020: 0,01 milj. USD2020: EBIT −0,67 milj. USD20202021: 0,01 milj. USD2021: EBIT −2,5 milj. USD20212022: 0,04 milj. USD2022: EBIT −2,5 milj. USD20222023: 0,02 milj. USD2023: EBIT −2,8 milj. USD20232024: 0,03 milj. USD2024: EBIT −2,6 milj. USD20242025: 0,07 milj. USD2025: EBIT −3,2 milj. USD20250,07−3,2
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Vivos Inc

Liiketoiminta

Osuus liikevaihdosta
Precision radionuclide therapy devices55 %

Y-90 based devices and therapies designed to deliver radiation to non-resectable tumors.

Animal therapy procedures35 %

IsoPet® treatments administered through veterinary and clinic settings.

Research and development services10 %

Development work on new isotope technologies and future cancer applications.

Tuotteet

Raportoitu · osuus liikevaihdosta
52,7%32,7%13,8%FY2025100 %
  • Iso Pet52,7 %
  • Services Treatments32,7 %
  • Certification13,8 %
  • Polymer0,4 %
  • Freight0,4 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

The company sells into oncology and veterinary treatment settings that use isotope-based therapies for tumors and other cancers. Its customer base includes clinics, physicians, and treatment partners that adopt the technology for either human oncology or animal therapy applications. Commercialization also depends on third-party manufacturing, distribution, licensing, and partnership arrangements.

Veterinary clinics and animal therapy centers

Buy or administer IsoPet® procedures for animal tumor treatment and related oncology care.

Human oncology clinics and hospitals

Potential future buyers of RadioGel™ and other precision radionuclide therapies for non-resectable tumors.

Clinical research and regulatory partners

Support studies, approvals, and evidence generation needed for broader commercialization.

Manufacturing and commercialization partners

Provide outsourced production, sales, distribution, and licensing capabilities.

Strategia

Vivos’ strategy centers on advancing regulatory approval for its Y-90 precision radionuclide therapy platform and expanding the clinical use of IsoPet® and related products. It also plans to rely on licensing, partnerships, and outsourced manufacturing and distribution to commercialize the technology in the U.S. and abroad.

Secure regulatory clarity and approvalsLyhyt aikaväli

FDA classification and approval timing determine the path to human commercialization.

Build recurring clinical usageKeskipitkä aikaväli

Broader clinic adoption is needed to scale IsoPet® and future therapy revenue.

Establish commercialization partnersKeskipitkä aikaväli

Third-party manufacturing and licensing reduce the need for a large internal sales force.

Maantiede

Vivos is headquartered in Washington State in the United States, and its current commercial activity has been concentrated in the Northwestern U.S. The company also describes a broader U.S. animal therapy marketing effort and a longer-term plan to pursue international approvals and licensing outside the United States.

Riskit

The business depends on regulatory outcomes, clinical evidence, and the ability to fund development until commercialization scales. It also faces financing risk, execution risk in outsourced manufacturing and distribution, and the normal adoption risk of a specialized medical device platform in a regulated healthcare market.

Järjestetty vakavuuden mukaan
Financing and going-concern riskKriittinen

The company has limited revenue and relies on external capital to fund operations.

Kohdistuu: Working capital and development funding

Regulatory approval riskKorkea

Commercialization depends on FDA classification and possible additional studies.

Kohdistuu: RadioGel™ and other precision radionuclide therapies

Commercialization execution riskKorkea

Success depends on third-party manufacturing, sales, distribution, and licensing.

Kohdistuu: U.S. and international rollout

Clinical adoption riskKeskitaso

Hospitals and clinics may adopt the therapy slowly without strong evidence and approvals.

Kohdistuu: Human oncology and veterinary markets

Kysy Clarifolta: Vivos Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition

Small revenue base makes timing of procedure-based and product-related revenue important.

Vaikutus: Can create quarter-to-quarter volatility in reported sales

Inventory and cost of goods sold

Hydrogel inventory and treatment usage affect when costs are recognized.

Vaikutus: Can shift gross margin and cost timing across periods

Stock-based compensation

Included within professional fees and can materially affect operating expense.

Vaikutus: Raises reported operating costs without cash outflow

Going-concern assessment

Limited cash and recurring losses require management judgment about continuation.

Vaikutus: Affects disclosure and investor assessment of solvency risk

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Vivos Therapeutics, Inc.

VVOS · Surgical & Medical Instruments & Apparatus

VivoSim Labs, INC.

VIVS · Biological Products, (No Diagnostic Substances)

iTonic Holdings Ltd

ITOC · Electromedical & Electrotherapeutic Apparatus

Seres Therapeutics, Inc.

MCRB · Pharmaceutical Preparations

OS Therapies Inc

OSTX · Pharmaceutical Preparations

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Päivitetty: 29.4.2026